publication date: Jan. 24, 2020
Surufatinib phase III study reaches primary endpoint in advanced pancreatic neuroendocrine tumors in China, trial to end early
The independent data monitoring committee of the phase III SANET-p study of surufatinib in advanced neuroendocrine tumors has recommended that the study end early as the pre-defined primary endpoint of progression free survival had already been met.
Hutchison China MediTech, a biopharmaceutical company, sponsors the trial.
Following the early success of this study, Chi-Med now plans to arrange a pre-New Drug Application meeting with the China National Medical Products Administration to discuss the preparation of the NDA for surufatinib for this indication.
“Following surufatinib’s NDA submission for the treatment of non-pancreatic neuroendocrine tumors, these positive results for pancreatic neuroendocrine tumors reinforce that surufatinib has the unique opportunity to address all advanced neuroendocrine tumors,” Christian Hogg, CEO of Chi-Med, said in a statement. “We believe that no targeted therapies are approved in China or globally for such a broad spectrum of neuroendocrine tumor disease.”
FDA granted Orphan Drug designation to surufatinib for the treatment of pancreatic neuroendocrine tumors last November. The China NDA for surufatinib for the treatment of advanced non-pancreatic neuroendocrine tumors was accepted for review by the NMPA, and was subsequently granted Priority Review status in December.
Pain control strategy reduces need for opioids in patients with head and neck cancer
Gabapentin is an effective alternative to standard pain-control drugs and can manage head and neck cancer pain and symptoms without the need for narcotics, a study published in Cancer found.
Roswell Park Comprehensive Cancer Center researchers conducted the study and found that gabapentin, a drug … Continue reading Surufatinib phase III study reaches primary endpoint in advanced pancreatic neuroendocrine tumors in China, trial to end early
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.